Furthermore, we reported the very potent therapeutic benefits of Roniciclib in targeting ESC-like signature genes in patients suffering from not only HR-NB but also other aggressive tumours in which c-Myc-regulated ESC-like signatures have been shown to contribute to oncogenesis. This evidence concerns the gene MYC and neoplasm.